o NoneEntity Type
0001659323
Iterum Therapeutics Ltd
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Iterum Therapeutics plc
Jurisdiction of Incorporation/OrganizationIRELAND 
Year of Incorporation/Organization
  o Over Five Years Ago
  x Within Last Five Years (Specify Year) 2015
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Iterum Therapeutics plc 
Street Address 1Street Address 2
 BLOCK 2 FLOOR 3, HARCOURT CENTRE HARCOURT STREET
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 DUBLIN IRELAND 2 (872) 225-6077 



3. Related Persons
Last NameFirst NameMiddle Name
FishmanCoreyN.
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
MatthewsJudithM.
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
DunneMichael
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
AhrensBrentonK.
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
ChinMark
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HeronPatrickJ.
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HuntRonaldM.
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
MalikShahzad
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
KellyDavid
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
BarrettLouise
Street Address 1Street Address 2
Block 2 Floor 3, Harcourt CentreHarcourt Street
CityState/Province/CountryZIP/Postal Code
DublinIRELAND2
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 Company Secretary

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-06-05 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 430 Park Avenue 4th Floor
City State/Province/CountryZIP/Postal Code
 New York NEW YORK 10022
State(s) of Solicitation x All States o Foreign/Non-US
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 2844627 USD o Indefinite
Total Amount Sold $ 2844627 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 Warrants to purchase 1,485,885 shares of common stock with exchange price of $1.62 per share and warrants to purchase 208,023 shares of common stock at an exercise price of $2.1031 per share. Total amounts assume full exercise.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 8


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 350000 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Iterum Therapeutics Charts.
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Iterum Therapeutics Charts.

Iterum Therapeutics Plc News

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
Monday 6 May 2024 (1 day ago) • GlobeNewswire Inc.
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
Monday 29 April 2024 (1 week ago) • GlobeNewswire Inc.
US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise
Thursday 28 March 2024 (1 month ago) • IH Market News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Thursday 28 March 2024 (1 month ago) • GlobeNewswire Inc.
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Friday 22 March 2024 (2 months ago) • GlobeNewswire Inc.
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)
Iterum Therapeutics Provides Business Update
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Wednesday 31 January 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 30 January 2024 (3 months ago) • Edgar (US Regulatory)
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Tuesday 30 January 2024 (3 months ago) • PR Newswire (US)
Form 8-K - Current report
Saturday 30 December 2023 (4 months ago) • Edgar (US Regulatory)

More Iterum Therapeutics Plc News Articles